Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Biotech-Focused VHCP Management’s Bullish Moves and New Picks

Page 1 of 2

Biotech stocks pop and drop on the smallest whims and whispers, which makes the biotechnology sector one of the most rewarding and volatile sectors out there. Retail investors interested in high-potential biotech stocks should definitely have a look at the pool of holdings managed by Baker Bros. Advisors, run by Julian Baker and Felix Baker, or Peter Kolchinsky’s RA Capital Management. In 2009, venture capital firm Venrock Associates formed Venrock Healthcare Capital Partners (VHCP) to invest in public and late-stage private healthcare companies. The VHCP team at Venrock Associates, overseen by Anders Hove and Bong Koh, seeks to leverage their venture expertise and in-depth data analysis to locate promising biotech companies within the public markets. Thus, we decided to lay out several noteworthy moves executed by VHCP Management during the first quarter of 2016 in an attempt to discover high-potential biotech companies.

Our backtests that covered the period between 1999 and 2012, showed that following the 15 most popular small-caps among hedge funds can help a retail investor beat the market by an average of 95 basis points per month (see more details here).

Beigene Ltd (ADR) (NASDAQ:BGNE)

 – Number of shares owned by VHCP (as of March 31): 51,000 ADSs

 – Value of VHCP’s holding (as of March 31): $1.50 Million

The healthcare arm of venture capital firm Venrock Associates acquired a new stake of 51,000 American Depositary Shares (ADSs) of Beigene Ltd (ADR) (NASDAQ:BGNE) during the January-to-March period, which were valued at nearly $1.50 million at the end of the period. In early February, the clinical-stage biopharmaceutical company completed its initial public offering on the NASDAQ stock exchange by selling 6.60 million ADSs at $24.00 per ADS. Each ADS represents 13 ordinary shares. Beigene seeks to become a leader in the discovery and development of innovative, molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The company is working on four clinical-stage drug candidates that have the potential to be best-in-class or first-in-class treatments. The ADSs of Beigene have declined by nearly 2% since the beginning of 2016, but are trading 15% above their IPO price. A total of 15 hedge funds monitored by Insider Monkey were invested in Beigene at the end of the March quarter, with the aforementioned Baker Bros. Advisors LP being one of them, owning 1.91 million ADSs of Beigene Ltd (ADR) (NASDAQ:BGNE) as of March 31.

Follow Beigene Ltd.
Trade (BGNE) Now!

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)

 – Number of shares owned by VHCP (as of March 31): 562,943

 – Value of VHCP’s holding (as of March 31): $1.59 Million

VHCP added a 562,943-share position in BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to its pool of holdings during the March quarter. The new position was valued at $1.59 million and accounted for 1.4% of the value of the fund’s portfolio. However, it should be noted that in a 13G filing reporting its holding as of March 16, Venrock reported aggregate ownership of 5.24 million shares, 473,101 of which were held by the main fund, with the rest of the shares being held by affiliated funds, so it’s likely that Venrock’s position remains much larger than that reported in its latest 13F filing.

BioCryst, which designs and develops small molecule drugs to block key enzymes involved in the pathogenesis of diseases has seen its shares plummet by 68% year-to-date. The huge decline in the shares of the company are mainly attributable to disappointing results from the OPuS-2 trial of orally-administered avoralstat for the treatment of hereditary angioedema (HAE) attacks. On the other hand, BioCryst revealed in early March that a preclinical study showed one of the company’s experimental antiviral drugs improved survival rates in mice infected with the Zika virus. RA Capital Management had 2.99 million shares of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) in its portfolio at the end of March.

Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Trade (NASDAQ:BCRX) Now!

We’ll take a look at three more big moves made by VHCP Management during the first quarter on the next page.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!